Kojima, Takashi
Hara, Hiroki
Tsuji, Akihito
Yasui, Hisateru
Muro, Kei
Satoh, Taroh
Ogata, Takashi
Ishihara, Ryu
Goto, Masahiro
Baba, Hideo
Nishina, Tomohiro
Han, Shirong
Sakata, Tomoko
Yatsuzuka, Naoyoshi
Doi, Toshihiko
Kato, Ken http://orcid.org/0000-0002-1733-5072
Clinical trials referenced in this document:
Documents that mention this clinical trial
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
https://doi.org/10.1200/jco.2024.42.3_suppl.345
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study
https://doi.org/10.1007/s10388-024-01053-z
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
https://doi.org/10.1007/s10388-022-00920-x
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
https://doi.org/10.1200/jco.2024.42.3_suppl.250
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 12 November 2021
Accepted: 4 April 2022
First Online: 7 June 2022
Declarations
:
: The study protocol and all amendments were approved by the appropriate ethics committee at each center. The study was conducted in accordance with the protocol, its amendments, and standards of the Declaration of Helsinki and International Good Clinical Practice guidelines. All patients provided written informed consent.
: Takahashi Kojima has received grants from MSD, Ono Pharmaceutical Co., Ltd., Astellas Amgen BioPharma, Taiho Pharmaceutical, Chugai Pharmaceutical Co. Ltd., and Shionogi and honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, MSD, Astellas Pharma, Merck, and Oncolys BioPharma. Hiroki Hara has received funding for medical writing assistance from MSD K.K.; grants from Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Elevar Therapeutics, GSK, Incyte, Merck Biopharma, MSD K. K., Ono, Pfizer, and Taiho Pharmaceutical; consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Lilly, MSD K. K., and Ono; and honoraria from Bayer, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, Merck Biopharma, MSD K. K., Ono, Sanofi, Taiho Pharmaceutical, Takeda, and Yakult Honsha. Akihito Tsuji has received grants from Taiho Pharmaceutical Co., Ltd., Sanofi K.K., Bayer Yakuhin, Ltd. and honoraria from Chugai Pharmaceutical Co., Ltd. and, Eli Lilly Japan K.K. Hisateru Yasui received a grant from MSD. Kei Muro has received grants from Sanofi, Astellas, Amgen, Solasia Pharma, Daiichi Sankyo, Parexel International, Taiho, MSD, Merck Serono, Pfizer, Ono Pharmaceutical Co., Ltd., and Takeda; consulting fees from Amgen, Ono Pharmaceutical Co., Ltd., and AstraZeneca; honoraria from Eli Lilly, Chugai Pharmaceutical Co. Ltd., Takeda, Ono Pharmaceutical Co., Ltd., Taiho, Sanofi, Bristol Myers Squibb, and Bayer; and served on advisory boards of AstraZeneca and Ono Pharmaceutical Co., Ltd. Taroh Satoh has received grants from MSD, Ono Pharmaceutical Co., Ltd., Yakult Honsha, Chugai Pharmaceutical Co. Ltd., Gilead Sciences, BeiGene, Eli Lily and Company, and Taiho Pharmaceutical Co., Ltd; and consulting fees from Takara-Bio Inc. Hideo Baba has received a grant from MSD K.K. Tomohiro Nishina has received a grant from MSD and honoraria from Ono Pharmaceutical Co., Ltd., Taiho, Takeda, Chugai Pharmaceutical Co. Ltd., and Daiichi Sankyo. Toshihiko Doi has received grants from Lilly, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen Pharma, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb, AbbVie, IQVIA, and Eisai; consulting fees from Sumitomo Dainippon, Taiho, Takeda, Chugai Pharmaceutical Co. Ltd. Pharma, AbbVie, Bayer, Rakuten Medical, and Otuska Pharma; honoraria from Bristol Myers Squibb, Rakuten Medical, Ono Pharma, Oncolys BioPharma, and Taiho; and advises on the boards of MSD, Daiichi Sankyo, Amgen, Novartis, Boehringer Ingelheim, Janssen Pharma, AbbVie, Bayer, and Astellas Pharma. Ken Kato has received grants from MSD, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, BeiGene, Shionogi, Merck Biopharma, Oncolys Biopharma, Chugai Pharmaceutical Co. Ltd., Bayer; honoraria from Ono and Bristol Myers Squibb; and advises on the boards of Bristol Myers Squibb, BeiGene, and Ono Pharmaceutical Co., Ltd. Masahiro Goto, Shirong Han, Ryu Ishihara, Takashi Ogata, Tomoko Sakata, and Naoyoshi Yatsuzuka report no conflict of interest.